Select Page

References

New York Gastroenterology Associates participates in clinical research trials to offer our patients more treatment options for their conditions, as well as to contribute to the knowledge and practice of Gastroenterology. Please see below the trials at NYGA that we are participating in. If you are interested in learning more about these trials, please contact our research coordinator Salitah Qureshi at 347-248-8719 or Salitah.qureshi@nyga.md.

Filter by Reference Type

Filter by Condition

Filter by Doctor

M20-371 (AbbVie)

Study Drug: ABBV-154
Study Drug administration: IV and Subcutaneous Injection
Principal Investigator: Jay Desai
Disease: Moderate to Severe Crohn’s Disease

Inclusion criteria: endoscopically and clinically active CD, failed biologics (biologic therapy include TNF antagonists, vedolizumab, ustekinumab)

Exclusion criteria: current fistulizing disease, abscess, ostomy or ileoanal pouch, bowel resection within last 3 months, positive for C Difficile, Hepatitis B or C, HIV

Status: Upcoming

EMERALD-1 (Morphic Therapeutic)

Study Drug: MORF-057
Study Drug administration: Oral
Principal Investigator: Jay Desai
Disease: Moderate to Severe Ulcerative Colitis

Inclusion criteria: endoscopically and clinically active UC, treatment naïve OR failed biologics (include TNF antagonists, vedolizumab, ustekinumab), corticosteroids, immunomodulators, or treatment naïve

Exclusion criteria: abscesses, strictures, ileostomy, colostomy, positive for C. Difficile, HIV, Hepatitis B or Hepatitis C

Status: Enrolling

Request Your Appointment Today